Transition Period and Young Adulthood in Patients with Childhood Onset Growth Hormone Deficiency (COGHD): Impact of Growth Hormone Replacement on Bone Mass and Body Composition

被引:0
作者
Doknic, Mirjana [1 ,2 ]
Stojanovic, Marko [1 ,2 ]
Markovic, Aleksandra [3 ]
机构
[1] Univ Clin Ctr Serbia, Neuroendocrine Dept, Clin Endocrinol Diabet & Metab Dis, Beograd 11000, Serbia
[2] Univ Belgrade, Fac Med, Belgrade 11000, Serbia
[3] Univ Banja Luka, Univ Clin Ctr Republ Srpska, Fac Med, Dept Endocrinol,Internal Med Clin, Banja Luka 78000, Bosnia & Herceg
关键词
transition period; GHD; GH therapy; bone; body composition; GH DEFICIENCY; MINERAL DENSITY; CLINICAL CHARACTERISTICS; SKELETAL-MUSCLE; SINGLE-CENTER; FINAL HEIGHT; THERAPY; ADOLESCENTS; CHILDREN; METABOLISM;
D O I
10.3390/ijms251910313
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aim of this review article is to highlight the consequences of COGHD after the end of linear growth on bone mass and body composition and the opposing beneficial effects of continuing GH replacement in the transition period and young adults. The role of growth hormone in the period of late adolescence and young adulthood is well established, mainly in achieving peak bone mass and a favorable body composition, characterized by muscle mass increase and fat mass reduction. Patients with childhood onset growth hormone deficiency (COGHD), after reaching the adult height, have a reduced bone mineral density and muscle mass with increased fat mass compared to healthy controls. Inadequate body composition is a predictor for cardiovascular risk, while low bone mass in early youth hallmarks the risk of osteoporosis and bone fractures in later life. Cessation of growth hormone replacement (GHr) after completion of growth will lead to delayed peak bone mass and unbalanced body composition with increased abdominal fat deposits. According to numerous clinical studies monitoring the effects of GH treatment on the physical and psychological status of patients with persistent GHD after completion of growth, we suggest continuing this treatment between 16 and 25 years of age. It is advised that GHr in the transition period be administered in intermediate doses between those for the pediatric population and those for the adult population. Usual daily GHr doses are between 0.3 and 0.5 mg but need to be individually optimized, with the aim of maintaining IGF-I in the age-specific normal range.
引用
收藏
页数:19
相关论文
共 103 条
  • [1] Parathyroid responsiveness to hypocalcemic and hypercalcemic stimuli in adult growth hormone deficiency after growth hormone replacement
    Ahmad, AM
    Hopkins, MT
    Thomas, J
    Durham, BH
    Fraser, WD
    Vora, JP
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 286 (06): : E986 - E993
  • [2] Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement
    Ahmid, M.
    Perry, C. G.
    Ahmed, S. F.
    Shaikh, M. G.
    [J]. ENDOCRINE CONNECTIONS, 2016, 5 (03): : R1 - R11
  • [3] An audit of the management of childhood-onset growth hormone deficiency during young adulthood in Scotland
    Ahmid, M.
    Fisher, V.
    Graveling, A. J.
    McGeoch, S.
    McNeil, E.
    Roach, J.
    Bevan, J. S.
    Bath, L.
    Donaldson, M.
    Leese, G.
    Mason, A.
    Perry, C. G.
    Zammitt, N. N.
    Ahmed, S. F.
    Shaikh, M. G.
    [J]. INTERNATIONAL JOURNAL OF PEDIATRIC ENDOCRINOLOGY, 2016,
  • [4] Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period: results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA
    Aimaretti, G.
    Attanasio, R.
    Cannavo, S.
    Nicoletti, M. C.
    Castello, R.
    Di Somma, C.
    Garofalo, P.
    Iughetti, L.
    Loche, S.
    Maghnie, M.
    Mazzanti, L.
    Saggese, G.
    Salerno, M.
    Tonini, G.
    Toscano, V.
    Zucchini, S.
    Cappa, M.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2015, 38 (03): : 377 - 382
  • [5] Aimaretti G, 2001, J Pediatr Endocrinol Metab, V14 Suppl 5, P1233
  • [6] Insights from an advisory board: Facilitating transition of care into adulthood in brain cancer survivors with acquired pediatric growth hormone deficiency
    Alter, Craig
    Boguszewski, Margaret
    Clemmons, David
    Dobri, Georgiana A.
    Geffner, Mitchell E.
    Kelepouris, Nicky
    Miller, Bradley S.
    Oh, Richard
    Shea, Heidi
    Yuen, Kevin C. J.
    [J]. GROWTH HORMONE & IGF RESEARCH, 2024, 74
  • [7] Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients
    Attanasio, AF
    Shavrikova, E
    Blum, WF
    Cromer, M
    Child, CJ
    Paskova, M
    Lebl, J
    Chipman, JJ
    Shalet, SM
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (10) : 4857 - 4862
  • [8] Improved adipose tissue metabolism after 5-year growth hormone replacement therapy in growth hormone deficient adults: The role of zinc-α2-glycoprotein
    Balaz, Miroslav
    Ukropcova, Barbara
    Kurdiova, Timea
    Vlcek, Miroslav
    Surova, Martina
    Krumpolec, Patrik
    Vanuga, Peter
    Gasperikova, Daniela
    Klimes, Iwar
    Payer, Juraj
    Wolfrum, Christian
    Ukropec, Jozef
    [J]. ADIPOCYTE, 2015, 4 (02) : 113 - 122
  • [9] Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis
    Barake, Maya
    Arabi, Asma
    Nakhoul, Nancy
    Fuleihan, Ghada El-Hajj
    El Ghandour, Sarah
    Klibanski, Anne
    Tritos, Nicholas A.
    [J]. ENDOCRINE, 2018, 59 (01) : 39 - 49
  • [10] Baroncelli GI, 2003, J PEDIATR ENDOCR MET, V16, P327